A comprehensive view of regeneron pharmaceuticals inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Regeneron partners with CRISPR drug developer Mammoth Biosciences to develop in vivo gene therapies; the US$100.0M deal combines Regeneron's viral vector technology with Mammoth's DNA editing platforms for 5.5 years, with option to extend
Published: April 25, 2024 by BioPharma Dive
US Patent Issued to Regeneron Pharmaceuticals on April 23 for "Methods and compositions for sensitization of tumor cells to immune therapy" (New York, New Jersey Inventors)
Published: April 24, 2024 by U.S. Fed News
US Patent Issued to REGENERON PHARMACEUTICALS on April 23 for "Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy" (New York Inventors)
Published: April 24, 2024 by U.S. Fed News
US Patent Issued to Regeneron Pharmaceuticals on April 23 for "Humanized IL-4 and IL-4RAlpha animals" (New York, California Inventors)
Published: April 24, 2024 by U.S. Fed News
US Patent Issued to Regeneron Pharmaceuticals on April 23 for "Antigen binding molecule formats" (New York Inventors)
Published: April 24, 2024 by U.S. Fed News

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count